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25(OH) vitamin D, while both vitamins equally increased
Reply from the Authorthe serum calcium x PO4 product and suppressed parathy-
We are pleased that Fournier et al also see the needroid hormone (PTH) levels and histologic osteoclastosis [2].
to validate the effects of new vitamin D analogues inThese data suggest either a negative direct effect of cal-
side-by-side comparisons with calcitriol. Indeed, it is ourcitriol on bone mineralization or a positive one on 25(OH)
contention that optimal validation of the effects of vita-or 24,25(OH)2 vitamin D metabolites. Interestingly, the
min D compounds on bone should be accompanied byfirst concept has been supported by recent experiments
histomorphometric analysis. The effects of 25 (OH) vita-performed in vitamin D receptor-deleted transgenic mice,
min D as raised by Fournier et al were deemed to bewhich showed a better mineralization of vitamin D re-
outside the scope and focus of our review. However, weceptor knockout mouse bone transplanted into wild-type
would also point out that while there are undoubtedly
mouse muscle, as compared to that of wild-type mouse multiple factors controlling parathyroid hormone (PTH)
bone [3]. gene transcription, including calcium, there is a large
Furthermore the equipotency of 25(OH) vitamin D body of evidence supporting the direct suppression of
and -calcidol on PTH and osteoclastosis challenged the PTH gene transcription by calcitriol interactions with its
overriding role of calcitriol on the prepro-PTH gene receptor [1–4]. Thus, as stated in our review, the need
expression via vitamin D receptor activation, unless it is to monitor PTH concentrations in patients with renal
accepted that the 25(OH) vitamin D may activate the vita- insufficiency treated with calcitriol so as to not oversup-
min D receptor, like calcitriol, because of its 103 higher press the peptide hormone is medically prudent, as it
will be in the evaluation of the next generation of vitamincirculating levels. This possibility is supported by our study
D analogues.in hemodialysis patients showing that PTH is inversely
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